Venezuela
+918770708752

Choosing Eribulin Mesylate Injection from a Pharmaceutical Supplier

Selecting eribulin requires more than matching a product name and vial price. You will be able to assess whether the medicine fits the intended oncology use, calculate realistic vial requirements, inspect the supplied batch and compare a Caracas supplier’s documentation, transport controls and regulatory readiness.

Key takeaways

  • Confirm the approved Venezuelan indication before requesting an eribulin quote.
  • Calculate the patient dose from body-surface area, not vial count.
  • Compare vial sizes, preparation instructions and unavoidable residual waste.
  • Request batch records, temperature evidence and the complete quality file.

Confirm the indication and clinical setting before requesting a quote

Eribulin is not a general-purpose chemotherapy substitute. Before requesting a quote for eribulin injection for hospitals, the oncology service must match the patient’s diagnosis, prior treatment and intended pathway with the product’s approved Venezuelan indication.

  1. Confirm metastatic or locally advanced breast cancer after prior anthracycline- and taxane-containing therapy, or unresectable or metastatic liposarcoma after prior anthracycline therapy. Use the locally registered product information, because approvals differ by jurisdiction.
  2. Obtain an oncologist’s prescription and document where eribulin sits in the treatment plan: the line of therapy, treatment intent and criteria for continuation or stopping.
  3. Confirm that the hospital can monitor complete blood counts and manage myelosuppression, especially neutropenia and febrile neutropenia, through its oncology service or an established referral pathway.

Do not treat a catalogue listing or a supplier’s generic cancer-treatment claim as evidence of suitability. If the diagnosis, prior anthracycline or taxane exposure, local indication, or monitoring arrangements do not align, a competitive price does not make the product appropriate.

Request the complete product monograph and pharmacovigilance contact before comparing quotations; these documents help the prescriber and pharmacy verify warnings, dose interruptions and the pathway for reporting suspected adverse reactions.

Calculate the dose from body-surface area, not from the vial count

A request for eribulin mesylate injection from a pharmaceutical supplier in Caracas must start with the patient’s body-surface area (BSA), not the number of vials offered. Apply the labelled dose of 1.4 mg/m² on days 1 and 8 of each 21-day cycle.

  • Multiply BSA by 1.4. A patient with a BSA of 1.8 m² requires 2.52 mg per administration.
  • Divide the required milligrams by the labelled concentration. At 0.44 mg/mL, 2.52 mg requires 5.73 mL before preparation losses. At 0.5 mg/mL, it requires 5.04 mL.
  • Divide the dose by the labelled amount in each vial, then round up. Three 1 mg single-dose vials are needed for 2.52 mg; unused drug is not a reason to reduce the dose.
  • Multiply the per-dose requirement by two for the standard cycle. The 1.8 m² example therefore needs 5.04 mg across days 1 and 8, or six 1 mg vials before preparation waste.

Confirm the concentration, vial fill, and single-dose status on the approved local label. The reference presentation is 0.5 mg/mL in a 2 mL vial containing 1 mg, so a quoted 0.44 mg/mL product cannot be treated as interchangeable without verification.

For toxicity, the labelled reductions are 1.1 mg/m² and then 0.7 mg/m². Do not ask a supplier to create an arbitrary lower strength; discontinue treatment if 0.7 mg/m² is not tolerated.

Compare presentation, preparation requirements and unavoidable vial waste

A 1.8 m² patient receiving 1.4 mg/m² needs 2.52 mg, so a hospital using 1 mg single-dose vials opens three vials and discards 0.48 mg. Compare the administered-dose cost, not the quoted vial price.

PresentationWhat to verifyCost and usability effect
Reference vial0.5 mg/mL, 2 mL, containing 1 mg eribulin mesylateThree vials supply the example dose; unused contents are unavoidable waste
Different concentration or fillmg/mL, total mg, vial volume and single-dose statusA cheaper vial can require more units or leave more residual product
Locally registered packExcipients, container, closure, carton and approved Spanish labelA product name alone does not prove that the vial is importable or usable

Ask the supplier to state the concentration and total milligrams in writing. Confirm that the presentation matches the Venezuelan-registered product; a vial labelled only with a trade name or “eribulin injection for hospitals” is not enough.

The pharmacy must also compare preparation instructions. Check whether the supplied label permits withdrawal directly from the vial or requires dilution, which diluent it names, the final volume, storage time after opening, and administration over 2–5 minutes. Preparation losses from syringe dead space or transfer devices add to the discarded amount.

For each proposed pack, calculate: vials opened × vial price, then add unavoidable preparation and disposal costs. Do not pool leftovers from single-dose vials unless the approved instructions and aseptic pharmacy process explicitly allow it. A lower unit price is not lower cost if it creates an extra opened vial per treatment day.

Inspect the batch and prove that shipment conditions were controlled

Do not release the vials to stock until the receiving pharmacist matches the shipment to its paperwork and temperature record. This check applies in Caracas or elsewhere in Venezuela; an anti cancer injection supplier in Caracas must prove control of the specific lot, not just display a product photograph or generic GMP claim.

  • Match the product name, 0.5 mg/mL concentration, 2 mL single-dose vial, lot number, expiry date and quantity against the purchase order and approved local presentation.
  • Inspect each carton and vial for a broken seal, leakage, cracks, damaged label, illegible print, particles, discoloration or an unexpected change in appearance. Quarantine any suspect unit.
  • Request the certificate of analysis for that batch. Check identity, assay, sterility, bacterial endotoxins, particulate matter, appearance and container-closure information where applicable.
  • Download the shipment’s temperature logger or obtain a signed temperature report covering dispatch, transit and delivery. Eribulin reference storage is 20–25°C, with permitted excursions of 15–30°C; routine refrigeration is not inherently required.
  • Ask for the supplier’s excursion report and disposition decision if the record leaves 15–30°C. Do not accept “kept cold” as proof of compliance.
  • Record the receiving date, carrier, carton condition, logger reading, lot numbers and the staff member who accepted delivery. Confirm that individual shipping units remain traceable.

Short remaining shelf life, missing identifiers or an unreviewed excursion can create waste and patient-safety risk even when the assay passes. Hold the lot until quality staff document a release decision.

Require the regulatory, quality and traceability file before purchase

An eribulin mesylate injection supplier in Caracas must show more than an Indian licence, WHO GMP certificate or product photograph. Request a dossier tied to the exact manufacturer, presentation and intended Venezuelan market before issuing a purchase order.

  • Venezuelan product registration, approved Spanish label and package insert, plus the current authorization covering importation and local distribution.
  • The Indian manufacturing licence, WHO GMP certificate and manufacturing-site details, checked against the name and address printed on the vial.
  • A batch-specific certificate of analysis reporting identity, assay, sterility, bacterial endotoxins, particulate matter, appearance and container-closure results.
  • Finished-batch traceability showing release date, expiry date, lot number, serialization or other pack identifiers, recall procedure and pharmacovigilance contact.
  • Qualified transport instructions for 20–25°C storage, permitted excursions of 15–30°C, excursion assessment and lot-level temperature records.
DocumentWhat it provesWhat it does not prove
Venezuelan registrationThe product is authorized for the stated market and indicationThat the delivered batch passed release testing
WHO GMP certificateThe site operates under a recognized quality systemVenezuelan marketing authorization
Batch certificate of analysisThe named lot met specified quality testsCorrect importation or uninterrupted transport
Transport and traceability recordsThe shipment and individual units can be investigatedClinical suitability for an unapproved use

An anti cancer injection supplier in Caracas should reconcile the vial concentration, fill volume, excipients and packaging with the Venezuelan-registered presentation, not rely on the product name. NIBA HEALTHCARE should be assessed by this same evidence file, not by its catalogue entry alone.

Related product

Eribulin Mesylate Injection

Anti Cancer Injection

Eribulin Mesylate Injection

Minimum order quanity 10 Vial Strength 0.44 mg/ml Packaging Type Vial Packaging Size 2 ml Vial STORAGE CONDITION Store below 30 Degree C Country of...

View product →

Frequently asked questions

  • What should a hospital confirm before requesting an eribulin quote?

    Match the patient’s diagnosis, prior treatment and intended care pathway with eribulin’s approved Venezuelan indication and the hospital’s clinical setting.

  • How should the eribulin dose be calculated?

    Calculate the prescribed dose from body-surface area and the applicable clinical protocol, then determine how many vials are needed.

  • What should buyers compare between eribulin injection presentations?

    Compare vial strength and volume, preparation requirements, administration instructions and the vial quantity likely to remain unused after dosing.

  • How can a buyer check shipment control and product traceability?

    Inspect the batch number, expiry date, packaging and temperature records, then request the regulatory, quality and traceability documents before purchase.

 2026-10-09T13:30:18

Keywords